title: Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro.
abstract: Recently, many research groups have examined the effect of apolipoprotein E (apoE) on beta-amyloid fibril (betaAf) formation in vitro. However, their data were somewhat controversial and no exact kinetic assessment of the role of apoE has thus far been available. We examined the effect of human apoE on betaAf formation in vitro, starting with various concentrations of freshly prepared beta-amyloid(1-40) (beta1-40) and using fluorescence spectroscopy with thioflavine T. When 50 microM of beta1-40 was incubated with a 1:1000 to 1:100 molar ratio of apoE, a dose-dependent inhibitory effect of apoE was observed. Both the nucleation and extension phases of betaAf formation in vitro were inhibited by apoE. On the other hand, when 300 microM of beta1-40 was incubated with a 1:100 molar ratio of apoE, the inhibitory effect of apoE was completely abolished. We then focused our study on the kinetics of the inhibitory effect of apoE on the extension phase of betaAf formation in vitro, utilizing the recently established first-order kinetic model of betaAf extension in vitro [Naiki, H., & Nakakuki, K. (1996) Lab. Invest. 74, 374-383]. The mathematical treatment of the data suggests that apoE inhibits the extension of betaAf in vitro, by making a complex with beta1-40, thus eliminating free beta1-40 from the reaction mixture. The equilibrium association constant with beta1-40 was practically the same among the three major recombinant apoE isoforms. These results indicate that the effects of apoE on betaAf formation in vitro is differential and could settle some of the controversy about beta-amyloid-apoE interaction in vitro.
authors.affiliation: Department of Pathology, Fukui Medical School, Japan. naiki@fmsrsa.fukui-med.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Naiki
authors.forename: F
authors.initials: F
authors.lastname: Gejyo
authors.forename: K
authors.initials: K
authors.lastname: Nakakuki
mesh_terms: D000544:Alzheimer Disease; D000682:Amyloid / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000648:ultrastructure; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000378:metabolism; D011108:Polymers; D011485:Protein Binding; D017433:Protein Structure, Secondary; D013050:Spectrometry, Fluorescence
chemical_list: D000682:Amyloid; D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D010446:Peptide Fragments; D011108:Polymers; C078592:amyloid beta-protein (1-40)